The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments.

To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.

当前严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的爆发对癌症患者的治疗决策提出了重大挑战，与癌症患者相比，癌症患者发生严重且致命的 SARS-CoV-2 感染的风险可能更高。与广大民众。医疗保健紧急情况迫使人们重新调整免疫抑制和潜在毒性治疗的风险和预期收益之间的日常评估。

为了指导米兰国家癌症研究所（伦巴第大区，意大利疫情爆发中心）的临床决策，我们制定了适应冠状病毒的机构建议，用于胃肠道癌症患者的系统治疗。在这里，我们描述了我们的日常临床实践因大流行爆发而发生的变化，旨在为全球面临同样挑战的医生提供有用的建议。